Global Biologic Medical Product Market Growth (Status and Outlook) 2025-2031

The global Biologic Medical Product market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources - human, animal, or microorganism - and may be produced by biotechnology methods and other cutting-edge technologies. Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Biologic Medical Product Industry Forecast” looks at past sales and reviews total world Biologic Medical Product sales in 2024, providing a comprehensive analysis by region and market sector of projected Biologic Medical Product sales for 2025 through 2031. With Biologic Medical Product sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologic Medical Product industry.

This Insight Report provides a comprehensive analysis of the global Biologic Medical Product landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biologic Medical Product portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biologic Medical Product market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologic Medical Product and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologic Medical Product.

This report presents a comprehensive overview, market shares, and growth opportunities of Biologic Medical Product market by product type, application, key players and key regions and countries.

Segmentation by Type:
Monoclonal Antibodies
Colony-Stimulating Factor
Interferon
Erythropoietin
Insulin
Vaccines
Growth Hormones
Others

Segmentation by Application:
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Pfizer
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Ganlee
United Laboratories
Teva Pharmaceutical
MYLAN
Sun Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.